Belgium· BE-AMP-SAM479155-00
Strensiq 40 mg/ml
A asfotase alfa product containing asfotase alfa, registered in Belgium by Alexion Europe. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Asfotase alfa is registered in 13 of 19 countries.
Countries holding a registration under ATC A16AB13 (asfotase alfa), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Asfotase alfa · ATC A16AB13
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of asfotase alfa costs, country by country.
Normalised to the WHO defined daily dose (21.4 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Asfotase alfa · price per daily dose (21.4 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1328.81
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Asfotase Alfa
- Manufacturer
- Alexion Europe
- Country
- Belgium (BE)
- ATC code
- A16AB13
- ATC class
- Asfotase alfa
- Defined daily dose
- 21.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Asfotase alfa in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandStrensiq 40 mg/ml, InjektionslösungAlexion Pharma GmbH
- CzechiaSTRENSIQAlexion Europe SAS, Levallois-Perret
- NorwayStrensiqAlexion Europe SAS (2)
- SpainSTRENSIQ 40 MG/ML SOLUCION INYECTABLEAlexion Europe Sas
- SwedenStrensiq 40 mg/ml Injektionsvätska, lösningAlexion Europe SAS
- IcelandStrensiqAlexion Europe SAS
- PolandStrensiqAlexion Europe SAS
- Japanアスホターゼ アルファ（遺伝子組換え）アレクシオンファーマ
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Strensiq
- Liechtenstein · Strensiq
- Norway · Strensiq
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d93a1fec-1e4d-45cd-be0e-f423ca4b94aa GET /v1/drugs/d93a1fec-1e4d-45cd-be0e-f423ca4b94aa?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Strensiq 40 mg/ml",
"name_fr": "Strensiq 40 mg/ml",
"name_nl": "Strensiq 40 mg/ml",
"amp_code": "SAM479155-00",
"strengths": [
"40.0000"
],
"pack_count": 2,
"substances": [
"Asfotase Alfa",
"Disodium Hydrogen Phosphate Heptahydrate",
"Sodium Chloride",
"Sodium Phosphate Monobasic Monohydrate"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Asfotase Alfa",
"authorisation_numbers": [
"EU/1/15/1015/001",
"EU/1/15/1015/002"
]
}See everything about asfotase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.